In the letter, Mr. Riis discussed the company’s position on drug affordability and listed three main initiatives the company will take that revolve around creating more pricing predictability, transforming the drug pricing system and reducing the burden of out-of-pocket costs to patients.
“We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make. We take this issue seriously and have been thinking about what we can do to better support patients,” Mr. Riss wrote in the letter. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”
Mr. Riis’ initiative follows the stance Allergan CEO Brent Saunders took against high drug prices in September when he promised to limit price increases through a social contract with consumers.
More articles on supply chain:
US regulators create national database to track truckers’ drug, alcohol testing records: 4 things to know
Global prescription drug spending to hit $1.5 trillion by 2021: 6 findings
How drug prices spurred a shouting match between 2 pharma CEOs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
